Axa’s Aerie Pharmaceuticals AERI Stock Holding History

Axa’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-173,120	Closed	-$10.7M	–	1395
2018 Q3	$10.7M	Hold	173,120	–	–	0.04%	464
2018 Q2	$11.7M	Buy	173,120 +2,203	+1%	+$123K	0.04%	405
2018 Q1	$9.27M	Sell	170,917 -1,731	-1%	-$96.8K	0.04%	467
2017 Q4	$10.3M	Sell	172,648 -33,069	-16%	-$2.01M	0.04%	460
2017 Q3	$10M	Sell	205,717 -2,863	-1%	-$156K	0.04%	433
2017 Q2	$11M	Buy	+208,580	New	+$9.71M	0.05%	404

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Axa's AERI Position: Q4 2018 in Review

Axa sold out of Aerie Pharmaceuticals (AERI) in Q4 2018, closing a stake of 173,120 shares — an estimated $10.7M sold.

Axa first reported a position in AERI in Q2 2017 and held it in 6 quarters. The position peaked at $11.7M in Q2 2018. 160 funds tracked by Wall St. Rank hold AERI as of Q4 2018.

Axa reported no remaining Aerie Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Axa sold 173,120 Aerie Pharmaceuticals shares in Q4 2018, an estimated $10.7M.
Axa first reported a position in Aerie Pharmaceuticals in Q2 2017 and held it in 6 quarters.
Axa's Aerie Pharmaceuticals position peaked at $11.7M in Q2 2018.
160 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2018.

Based on Axa's 13F filing for Q4 2018, filed 13 Feb 2019.